Johnson & Johnson (NYSE:JNJ) Stock, Quote.Headers.trade-ideas

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Wall Street Bulls

Analyst Color

Equities

Long Ideas

News

Markets

Trading Ideas

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip equities to rise further as they forecast a better return potential.



Dow’s Performance In 2024

Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025

Stethoscope,Laying,On,Medicine,White,Pills,Money,With,Rx,Prescription

Biotech

Government

Health Care

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

FDA And CDC Involvement

Large Cap

The FDA delays Johnson &amp; Johnson&#39;s SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy

FDA Rejects Johnson &amp; Johnson&#39;s Injectable Version Of Approved Drug For Lung Cancer

The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip equities to rise further as they forecast a better return potential.
Dow&#8217;s Performance In 2024
The Dow Jones Industrial Average index hit a record eight 1,000-point milestones this year. It started the year around the 37,000 level and breached the 45,000 level at the beginning of December. It took only seven trading days for the index to go from 44,000 to 45,000, the second fastest 1,000-point milestone ever.
Following that the index also saw one of its longest 10-day losing streak, the first ever since 1974. These 10 days of underperformance stems from a confluence of factors. 
The Dow doesn&#8217;t include all &#8220;Magnificent 7&#8221; stocks like Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>). The recent inclusion of Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in the Dow has also pulled the index down because of the stock&#8217;s underperformance.
Dow&#8217;s constituent UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has experienced a substantial decline this month following the tragedy with its CEO&#8217;s shooting. Moreover, in essence, the Dow&#8217;s historical advantage of its price-weighted indexing has become a significant disadvantage in today&#8217;s market. This is because, unlike market capitalization-weighted indices, higher-priced stocks have more weight in the calculation of a price-weighted index.
<h4 class="wp-block-heading">Dow Jones Stocks With The Best And Worst Return Potential</h4>
Analysts still expect that a group of stocks led by Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), UnitedHealth and Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) within the Dow will rise even more, according to estimates compiled by <a href="https://www.benzinga.com">Benzinga</a>. Others on the list are the Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
To be sure, analysts keep updating their forecasts based on company performance and may change their estimates as the new earnings season begins.
Selection Criteria:
<ul>
<li>The thirty blue-chip stocks in Down Jones.</li>
</ul>
<ul>
<li>The highest and lowest return potential is based on the average 12-month target prices from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.</li>
</ul>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Companies</td>
<td>M-Cap</td>
<td>Highest PT ($/Share)</td>
<td>Lowest PT ($/Share)</td>
<td>Consensus PT ($/Share)</td>
<td>Upside/Downside Potential</td>
</tr>
<tr>
<td>Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</td>
<td>176.73B</td>
<td>515</td>
<td>174</td>
<td>331.35</td>
<td>31.68%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>460.26B</td>
<td>675</td>
<td>460</td>
<td>608.16</td>
<td>28.95%</td>
</tr>
<tr>
<td>Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)</td>
<td>86.71B</td>
<td>450</td>
<td>249</td>
<td>371.19</td>
<td>24.08%</td>
</tr>
<tr>
<td>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>2,365.04B</td>
<td>290</td>
<td>197</td>
<td>247.05</td>
<td>23.82%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>347.83B</td>
<td>215</td>
<td>40</td>
<td>168</td>
<td>22.41%</td>
</tr>
<tr>
<td>Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</td>
<td>256.71B</td>
<td>212</td>
<td>160</td>
<td>179.36</td>
<td>21.42%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc (NYSE: MRK</td>
<td>248.03B</td>
<td>155</td>
<td>104</td>
<td>126.24</td>
<td>20.76%</td>
</tr>
<tr>
<td>Salesforce Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crm#NYSE">CRM</a>)</td>
<td>328.87B</td>
<td>450</td>
<td>236</td>
<td>378.52</td>
<td>20.60%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>3,246.07B</td>
<td>600</td>
<td>465</td>
<td>508</td>
<td>18.21%</td>
</tr>
<tr>
<td>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>622.63B</td>
<td>375</td>
<td>252</td>
<td>318.42</td>
<td>17.69%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Benzinga.com (Data as of Dec. 22, 2024)</figcaption></figure>
See Also: <a href="https://www.benzinga.com/24/12/42430296/carson-researchs-50-year-study-suggests-that-the-26-months-old-bull-market-is-far-from-over">Is The 26-Month Bull Market Over? Here Is What Carson Research&#8217;s 50-Year Old Study Tells Us</a>
<h3 class="wp-block-heading">Caterpillar Inc</h3>
<ul>
<li>Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has the highest return potential of 31.68% among the Dow Jones constituents.</li>
</ul>
<ul>
<li>The 28 analysts tracking the company have a consensus price target of $331.35 per share, according to <a href="https://www.benzinga.com/quote/CAT/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Truist Securities&#8217; Jamie Cook raised the price target from $454 to $471 per share on Dec. 19, 2024 as he expects significant investments in infrastructure, likely driven by government initiatives and private sector projects to fuel demand for Caterpillar&#8217;s equipment.</li>
</ul>
<ul>
<li>Citigroup analyst Kyle Menges maintained a &#8216;buy&#8217; rating on the company and raised the price target from $435 to $460 apiece on Dec. 9, 2024.</li>
</ul>
<ul>
<li>On Dec. 9, JPMorgan analyst Tami Zakaria also reaffirmed her bullish stance on Caterpillar, maintaining a &#8216;buy&#8217; rating on the stock. Concurrently, she raised the firm&#8217;s price target for Caterpillar from $500 to $515 per share.</li>
</ul>
<h3 class="wp-block-heading">UnitedHealth Group</h3>
<ul>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has the second highest return potential of 28.95% among the Dow Jones constituents.</li>
</ul>
<ul>
<li>The 26 analysts tracking the company have a consensus price target of $331.35 per share, according to <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">Benzinga</a>.</li>
</ul>
<ul>
<li>Oppenheimer raised its price target to $640 from $610 apiece on Dec.6, 2024. The primary reason for the price target increase is that the Oppenheimer analyst is updating their financial model. This update appears to be based solely on the publicly available information disclosed by UnitedHealth in their 8-K filing.</li>
</ul>
<ul>
<li>Stephens &amp; Co raised its target price to $675 from $605 per share on Dec. 5, 2024, after conducting a detailed review of the 2025 guidance metrics that UnitedHealth had shared before the fatal shooting of CEO Brian Thompson that led to the cancellation of their investor conference.</li>
</ul>
<ul>
<li>Deutsche Bank also increased its target from $595 to $625 apiece as it believes investor positioning into the event is mostly neutral to positive, with almost no one expecting a negative revision versus the third quarter outlook.</li>
</ul>
<h3 class="wp-block-heading">Sherwin-Williams Company</h3>
<ul>
<li>Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) has a return potential of 24.08% going into 2025.</li>
</ul>
<ul>
<li>A consensus price target of $371.19 per share was maintained by 25 analysts that track the company, as per <a href="https://www.benzinga.com/quote/SHW/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Greg Melich from Evercore ISI raised the price target of the Ohio-based paints, coatings and related products manufacturer to $420 from $400 per share on Nov. 7, 2024.</li>
</ul>
<ul>
<li>RBC Capital&#8217;s Arun Viswanathan lowered his target on the company from $455 to $446 per share on Oct. 24, 2024. While acknowledging that third-quarter results might not have met investor expectations, Viswanathan emphasized the company&#8217;s potential for market share gains and the positive impact of its upcoming price increase scheduled for January 2025.</li>
</ul>
<ul>
<li>Citigroup adjusted its price target from $430 to $420 apiece on Oct. 24 as it anticipates choppy demand in the first half of 2025, which could hinder the rapid pass-through of interest rate cuts.</li>
</ul>
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42383725/trump-administrations-deregulation-efforts-to-lift-energy-oil-and-gas-sectors-ai-frenzy-to-aid-faang-stocks-and-nvidia-says-fintech-insider">Trump&#8217;s Deregulation Efforts To Benefit Energy, Oil And Gas Sectors, While AI Frenzy Will Boost FAANG Stocks And Nvidia, Says Fintech Insider</a>
<h3 class="wp-block-heading">Amazon.com Inc</h3>
<ul>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has a return potential of 23.82% going into 2025.</li>
</ul>
<ul>
<li>A consensus price target of $247.05 per share was maintained by 39 analysts that track the company, as per <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Tigress Financial&#8217;s Ivan Feinseth umped is price target from $245 to $290 apiece on Dec.20, 2024 as it believes Amazon is well-positioned for continued success, driven by robust retail trends, effective utilization of generative AI and its fulfillment network, and the strategic integration of AI across its entire business.</li>
</ul>
<ul>
<li>The expectations of strong long-term growth driven by operational efficiency and sustained momentum across its business segments led Bernstein to raise its target price from $235 to $265 per share on Dec. 18, 2024.</li>
</ul>
<ul>
<li>According to JPMorgan analyst Douglas Anmuth, Amazon is a best idea for 2025, and confidence in AWS growth in the months to come is a major reason for that. He raised its target price from $250 to $280 apiece on Dec. 18, 2024.</li>
</ul>
<h3 class="wp-block-heading">Johnson &amp; Johnson</h3>
<ul>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) has the fifth highest return potential in Dow of 22.41% going into 2025.</li>
</ul>
<ul>
<li>The 21 analysts tracking the company have a consensus price target of $168 apiece, according to <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Citigroup&#8217;s Joanne Wuensch lowered Johnson &amp; Johnson&#8217;s price target from $185 to $175 per share while maintaining a &#8216;buy&#8217; rating on Dec. 11, 2024.</li>
</ul>
<ul>
<li>BofA Securities reinstated coverage of Johnson &amp; Johnson with a &#8216;neutral&#8217; rating and a $166 price target on Dec. 10, 2024. BofA notes that J&amp;J&#8217;s current valuation premium to peers may limit upside potential. However, the analyst acknowledges a &#8220;fairly interesting&#8221; pipeline and anticipates that resolving the talc litigation in 2025 would be beneficial. This analysis was part of BofA&#8217;s broader coverage initiation of 11 large-cap U.S. pharmaceutical and biotechnology companies.</li>
</ul>
<ul>
<li>Wolfe Research analyst Alexandria Hammond commenced coverage of Johnson &amp; Johnson with an &#8216;outperform&#8217; recommendation and established a price target of $190 per share on Nov. 15, 2024</li>
</ul>
<h3 class="wp-block-heading">Chevron Corporation</h3>
<ul>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) has a return potential of 21.42% going into 2025.</li>
</ul>
<ul>
<li>The 24 analysts tracking the company have a consensus price target of $179.36 apiece, according to <a href="https://www.benzinga.com/quote/CVX/analyst-ratings">Benzinga</a>.</li>
</ul>
<ul>
<li>Piper Sandler analyst Ryan Todd reduced his price target on the company from $184 to $173 per share on Dec. 19, 2024, while maintaining a &#8216;buy&#8217; rating. Piper Sandler suggests the valuation gap between Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron implies a probability of over 65% of the Hess Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) deal failing out. This scenario presents a potential 15%-25% upside, while a successful deal offers a 5%-10% downside ahead of the upcoming arbitration.</li>
</ul>
<ul>
<li>Despite this deal uncertainty, Piper expects Chevron to deliver strong portfolio performance in 2025, driven by project starts and controlled capital expenditures. This is projected to result in a significant free cash flow increase of $6-$7 billion.</li>
</ul>
<ul>
<li>Wells Fargo analyst Roger Read raised his target price from $171 to $188 apiece on Dec. 9, 2024</li>
</ul>
<ul>
<li>Truist Securities raised its price target on Chevron to $160 from $155 while maintaining a &#8216;hold&#8217; rating, on Dec. 6, 2024. The analyst highlights Chevron&#8217;s significant inventory, including ample royalties, and expects improved capital efficiency to drive a cash flow inflection in the coming year.</li>
</ul>
<h3 class="wp-block-heading">Merck &amp; Co Inc</h3>
<ul>
<li>Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) has the seventh highest return potential in Dow of 20.76% going into 2025.</li>
</ul>
<ul>
<li>The 27 analysts tracking the company have a consensus price target of $126.24 apiece, according to <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">Benzinga</a>.</li>
</ul>
<ul>
<li>BMO Capital Markets downgraded Merck to &#8216;market perform&#8217; from &#8216;outperform&#8217; lowering the price target from $136 to $105 apiece, on Dec. 20, 2024. The downgrade reflects concerns about the company&#8217;s Gardasil franchise in China and the potential revenue gap as Keytruda faces increased competition from biosimilars and generic drugs.</li>
</ul>
<ul>
<li>Tim Anderson from BofA Securities maintains his bullish stance on Merck with a &#8216;buy&#8217; rating, while adjusting the price target downward to $121 from $127 per share, on Dec. 10, 2024.</li>
</ul>
<ul>
<li>Truist analyst Robyn Karnauskas reaffirms a &#8216;buy&#8217; rating for Merck on Nov. 7, 2024, but lowers the price target to $130 from $132 apiece.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42642834/market-breadth-turns-positive-after-a-rare-14-day-negative-streak-history-suggests-gains-ahead">Market Breadth Rebounds As Risk Appetite Makes A Comeback: This Analyst Predicts Gains Ahead After S&amp;P 500&#8217;s Record Negative Streak</a></li>
</ul>
Photo courtesy: Shutterstock

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

On Monday, the U.S. Food and Drug Administration issued a complete response letter (CRL) to Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Biologics License Application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.
The CRL is <a target="_blank" href="https://www.jnj.com/media-center/press-releases/update-on-u-s-regulatory-review-of-subcutaneous-amivantamab" rel="noreferrer noopener">related</a> to observations as part of a standard pre-approval inspection at a manufacturing facility.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">Johnson &amp; Johnson Challenges Government Drug Pricing Dispute Over Two Drugs</a>
The CRL is unrelated to the product formulation or the efficacy and safety data submitted in the regulatory application, and the FDA has not requested any additional clinical studies.
The CRL does not impact the currently approved intravenous (IV) formulation of Rybrevant&nbsp;(amivantamab-vmjw).
&#8220;We&#8217;re working closely with the FDA to bring SC amivantamab to patients as quickly as possible and are confident in our path to resolution,&#8221; said Yusri Elsayed, Global Therapeutic Area Head, Oncology, Innovative Medicine,&nbsp;Johnson &amp; Johnson.
&#8220;Backed by interim overall survival data showing a strong favorable trend compared to osimertinib, we believe strongly in the robust efficacy and safety of RYBREVANT — both as a standalone treatment and in combination with LAZCLUZE — for EGFR-mutated advanced lung cancer,&#8221; Elsayed added.
AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) sells osimertinib under the Tagrisso name.
The BLA is based on the Phase 3 PALOMA-3 study results, presented at the 2024 American Society of Clinical Oncology Annual Meeting and published in the&nbsp;<a href="https://ascopubs.org/doi/10.1200/JCO.24.01001" target="_blank" rel="noreferrer noopener">Journal of Clinical Oncology</a>.
In August 2024, the FDA granted a Priority Review for the BLA for SC amivantamab as a treatment for patients with NSCLC with EGFR exon 19 deletions or L858R substitution mutations. RYBREVANT is currently approved in over 60 countries worldwide.
JNJ Price Action: Johnson &amp; Johnson stock is up 1.26% at $145.64&nbsp;at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/12/42532242/salesforce-supercharges-adecco-vivint-with-ai-details" target="_blank" rel="noreferrer noopener">Salesforce Supercharges Adecco &amp; Vivint With AI: Details</a></li>
</ul>
Photo: Shutterstock

FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer

<a href="https://www.wsj.com/health/healthcare/j-j-accuses-big-health-insurer-of-helping-drain-its-drug-copay-funds-4b425811?mod=latest_headlines">https://www.wsj.com/health/healthcare/j-j-accuses-big-health-insurer-of-helping-drain-its-drug-copay-funds-4b425811?mod=latest_headlines</a>
&nbsp;
<a href="https://www.wsj.com/market-data/quotes/JNJ">Johnson &amp; Johnson</a> has sued divisions of health insurer <a href="https://www.wsj.com/market-data/quotes/CI">Cigna</a>, accusing them of working with a drug-benefit middleman to drain J&amp;J <a href="https://www.wsj.com/articles/patients-lose-access-to-free-medicines-amid-spat-between-drugmakers-health-plans-cca15b58?mod=article_inline">financial-assistance funds earmarked for patients</a> taking some of its pricier drugs.
The move by J&amp;J widens litigation the healthcare giant <a href="https://www.wsj.com/articles/j-j-sues-drug-benefit-middleman-over-use-of-drug-cost-assistance-program-11651698029?mod=article_inline">initiated in 2022</a> against a middleman, SaveOnSP LLC, and is a new flare-up of long-running tension over drug prices among manufacturers, insurers, pharmacy-benefit managers and other middlemen in recent years.

Legal

"J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds; Pharmaceutical company claims Cigna units worked with SaveOn and caused it to pay more than $100 million in copay assistance than it would have otherwise" - WSJ

Financial giants have made a conspicuous bearish move on Johnson &amp; Johnson. Our analysis of options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed 10 unusual trades.
Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $272,347, and 4 were calls, valued at $162,746.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $180.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $130.0 to $180.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734115615_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.8</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$145.00</td>
<td>$55.5K</td>
<td>140</td>
<td align="right">102</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.85</td>
<td>$9.65</td>
<td>$9.85</td>
<td>$155.00</td>
<td>$52.2K</td>
<td>3.4K</td>
<td align="right">105</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.25</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$155.00</td>
<td>$50.0K</td>
<td>3.4K</td>
<td align="right">205</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.9</td>
<td>$9.65</td>
<td>$9.9</td>
<td>$155.00</td>
<td>$49.5K</td>
<td>3.4K</td>
<td align="right">155</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.9</td>
<td>$9.7</td>
<td>$9.9</td>
<td>$155.00</td>
<td>$49.5K</td>
<td>3.4K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 3,379,283, with JNJ's price down by -0.06%, positioned at $146.15.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>Professional Analyst Ratings for Johnson &amp; Johnson</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $177.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Johnson &amp; Johnson, targeting a price of $175. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Neutral, setting a price target of $166. 
&#x2A; Reflecting concerns, an analyst from Wolfe Research lowers its rating to Outperform with a new price target of $190.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Media

AMGN

EXEL

GILD

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
On Wednesday, JPMorgan analyst Doug Anmuth maintained Netflix with an Overweight and raised the <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">price target from $850 to $1,010.</a>
 &#8220;It is absolutely true that they're not doing as well as Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>),&#8221; Cramer said when asked about Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). &#8220;But can we just remember Lisa Su has built an amazing company?&#8221; He recommended buying the stock, saying that the stock is &#8220;actually cheap.&#8221;
On Monday, AMD named Tim Keating as senior vice president, Government Relations and Regulatory Affairs.
Cramer said he prefers Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) over Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>). He added, &#8220;I don't want you to sell Constellation Energy, it has a habit of bouncing back because it's really involved in the data center, but it has got way too much volatility for me.&#8221;
On Nov. 22, Morgan Stanley analyst David Arcaro maintained Constellation Energy with an Overweight and lowered the price target from $323 to $322.
&#8220;Even with the talc litigation, I do want to buy it down here,&#8221; Cramer said when asked about Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
On Wednesday, Citigroup analyst Joanne Wuensch maintained Johnson &amp; Johnson with a Buy and lowered the price target from $185 to $175.
Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is a &#8220;very good&#8221; company, Cramer said. &#8220;The stock has been straight up. And, I've got to tell you, after that last quarter, I understand why it's straight up. It was probably mispriced when it came public.&#8221;
On Dec. 5, Rubrik posted better-than-expected quarterly results.
When asked about JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), he said, &#8220;It's too much of a stretch for me.&#8221;
On Monday, Bernstein analyst Robin Zhu upgraded JD.com from Market Perform to Outperform and raised the price target from $43 to $46.
Price Action:
<ul>
<li>AMD shares gained 1.9% to settle at $130.15 on Wednesday.</li>
<li>Constellation Energy shares gained 1.8% to close at $236.60.</li>
<li>Rubrik shares gained 1.7% to settle at $70.42 on Wednesday.</li>
<li>JD.Com shares fell 3.4% to $38.21 on Wednesday.</li>
<li>Johnson &amp; Johnson shares fell 1.7% to close at $146.64 on Wednesday.</li>
<li>Netflix shares gained 2.5% to settle at $936.56 on Wednesday.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a></li>
</ul>
Image: Shutterstock

NFLX

RBRK

Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix

CNBC&#8217;s Jim Cramer expressed strong buying conviction for Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) during Wednesday&#8217;s Lightning Round on &#8220;Mad Money,&#8221; as the streaming giant&#8217;s shares traded near $934 amid <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">broader tech market strength</a>.
What Happened: Cramer&#8217;s <a href="https://www.cnbc.com/2024/12/11/cramers-lightning-round-netflix-is-a-buy.html">recommendation</a> comes as JPMorgan analyst Doug Anmuth raised his price target on Netflix to $1,010 from $850, citing robust subscriber growth and <a href="https://www.benzinga.com/news/24/12/42439988/why-netflix-stock-is-rising">expanding ad revenue</a>. 
The platform recently achieved a milestone with its Jake Paul vs. Mike Tyson boxing match, which became the most-streamed sporting event ever with 60 million households watching live.
Netflix&#8217;s ad-supported tier has reached 70 million monthly active users and is projected to hit 120 million by late 2025. The company is expected to add 10 million subscribers in the fourth quarter, according to JPMorgan&#8217;s estimates.
During the same Lightning Round, Cramer also endorsed Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), calling it &#8220;cheap&#8221; despite lagging behind NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). He expressed cautious optimism about Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) &#8220;even with the talc litigation,&#8221; while showing less enthusiasm for JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), which he described as &#8220;too much of a stretch.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">Nasdaq Surges Past 20,000 For First Time, Driven By Tech Gains And Rate Cut Hopes</a>
Why It Matters: The endorsement came during a historic day for tech stocks, as the Nasdaq Composite <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">surpassed 20,000 points</a> for the first time, closing at 20,034, marking a 1.77% gain.
The stock picks came as <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">the S&amp;P 500 rose 0.82% to 6,084</a>, though the Dow Jones Industrial Average declined by 99.27 points to 44,148.
Price Action: Netflix Inc&#8217;s stock price rose to $936.56, up 2.54% on Wednesday. After hours, the price remained unchanged. Year to date, the stock has surged by $468.06, marking an increase of 99.91%. 
According to <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">data from Benzinga Pro</a>, Netflix has a consensus price target of $810.45 from 29 analysts, with a high of $1100 and a low of $550. The latest ratings from JP Morgan, Citigroup, and Canaccord Genuity suggest an average target of $956.67, implying a 2.43% upside.
Netflix&#8217;s stock has increased from $450.76 to $935.27 over the 52 weeks, with a market capitalization of $399.25 billion and a P/E ratio of 51.63. Its RSI is currently at 73.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11212832/Screenshot-2024-12-12-at-7.57.40%E2%80%AFAM-1024x378.png" alt="" class="wp-image-688609" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42452165/bitcoin-ethereum-dogecoin-spike-after-inflation-data-matches-expectations-top-analyst-foresees-new-btc-ath-if-it-stays-above-this-level">Bitcoin, Ethereum, Dogecoin Spike After Inflation Data Matches Expectations: Top Analyst Foresees New BTC ATH If It Stays Above This Level</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance

Citigroup analyst Joanne Wuensch maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Buy and lowers the price target from $185 to $175.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Johnson & Johnson, Lowers Price Target to $175

On Monday, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42397184/belantamab-mafodotin-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-i" rel="noreferrer noopener">DREAMM-7 trial</a>.
The trial assessed Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex (daratumumab) in combination with bortezomib plus dexamethasone (DVd) as a second line or later treatment for relapsed or <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">refractory multiple myeloma</a>.
These data were featured at the American Society of Hematology Annual Meeting and Exposition.
With a median follow-up of 39.4 months, the analysis presented shows a statistically significant 42% reduction in the risk of death among patients receiving the Blenrep combination (n=243) versus the Darzalex arm (n=251) (HR 0.58).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37540837/gsks-withdrawn-multiple-myeloma-drug-shows-encouraging-combination-therapy-data-in-second-late-st" rel="noreferrer noopener">GSK&#8217;s Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study</a>
Although the median overall survival (mOS) was not reached in either arm of the study, the projected mOS for BVd is 84 months compared to 51 months for the Darzalex combo arm.
The three-year overall survival rate was 74% in the Blenrep combination arm and 60% in the daratumumab combination arm.
The survival benefit favoring Blenrep over Darzalex was seen as early as four months and was sustained over time.
The Blenrep combination also showed statistically significant superiority over the Darzalex combination on the key secondary endpoint of minimal residual disease (MRD) negativity (no detectable cancer cells).
The greater than 2.5-fold improvement in the rate of MRD negativity seen at the time of the primary analysis for patients who received BVd can now be declared statistically significant after the positive overall survival readout based on the predefined testing procedure.
In addition to OS and MRD negativity, the Blenrep combination resulted in clinically meaningful improvements in all key secondary efficacy endpoints compared to the daratumumab combination, including duration of response (DOR) and progression-free survival.
Eye-related side effects, a known risk of treatment with Blenrep, were generally manageable and resolvable with dose modification and led to a low (10%) treatment discontinuation rate.
Price Action: GSK stock was down 1.77% at $35.35 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42418571/cervomeds-dementia-candidate-fails-in-mid-stage-study-stock-plummets" target="_blank" rel="noreferrer noopener">CervoMed&#8217;s Dementia Candidate Fails In Mid-Stage Study, Stock Plummets</a></li>
</ul>
Photo by HJBC via Shutterstock

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XRAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$40.5K</td>
<td>3.2K</td>
<td>2.1K</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$30.0K</td>
<td>8.4K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$50.00</td>
<td>$86.8K</td>
<td>9.6K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LFST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.00</td>
<td>$35.0K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$42.00</td>
<td>$33.0K</td>
<td>536</td>
<td>281</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$95.00</td>
<td>$44.7K</td>
<td>439</td>
<td>161</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$145.00</td>
<td>$26.1K</td>
<td>2.0K</td>
<td>95</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$470.00</td>
<td>$33.2K</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$65.00</td>
<td>$29.1K</td>
<td>278</td>
<td>11</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$470.00</td>
<td>$29.0K</td>
<td>1</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For XRAY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), we notice a call option trade that happens to be neutral, expiring in 128 day(s) on April 17, 2025. This event was a transfer of 225 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $40.5K, with a price of $180.0 per contract. There were 3202 open contracts at this strike prior to today, and today 2122 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 400 contract(s) at a $9.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $75.0 per contract. There were 8401 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 482 contract(s) at a $50.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $86.8K, with a price of $180.0 per contract. There were 9650 open contracts at this strike prior to today, and today 1214 contract(s) were bought and sold. 
• Regarding LFST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $70.0 per contract. There were 1847 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on January 17, 2025. This event was a transfer of 314 contract(s) at a $42.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $33.0K, with a price of $105.0 per contract. There were 536 open contracts at this strike prior to today, and today 281 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 101 day(s) on March 21, 2025. This event was a transfer of 50 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $44.7K, with a price of $895.0 per contract. There were 439 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 67 contract(s) at a $145.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $26.1K, with a price of $390.0 per contract. There were 2061 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a call option trade that happens to be neutral, expiring in 283 day(s) on September 19, 2025. This event was a transfer of 20 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $1660.0 per contract. There were 22 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be neutral, expiring in 402 day(s) on January 16, 2026. This event was a transfer of 11 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.1K, with a price of $2654.0 per contract. There were 278 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on January 24, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $2900.0 per contract. There were 1 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFST

RXRX

VKTX

VRTX

XRAY

10 Health Care Stocks With Whale Alerts In Today's Session

Ratings for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $191.2, a high estimate of $215.00, and a low estimate of $162.00. Experiencing a 0.02% decline, the current average is now lower than the previous average price target of $191.23. 
<img src="https://www.benzinga.com/files/images/story/2024/1733842913_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Johnson &amp; Johnson is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$166.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$162.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Johnson &amp; Johnson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>About Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Johnson &amp; Johnson's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.25% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 11.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.8%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.5%, the company showcases effective utilization of assets.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average at 0.51, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 15 Takes On Johnson & Johnson

B of A Securities analyst Tim Anderson reinstates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and announces $166 price target.

Initiation

B of A Securities Reinstates Neutral on Johnson & Johnson, Announces $166 Price Target

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy

Reported Sunday, Johnson & Johnson Highlights TECVAYLI's Role In Advancing Frontline Multiple Myeloma Care With 100% MRD-Negative Results At ASH 2024

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced data from&nbsp;the Phase 3 AQUILA study showing that DARZALEX FASPRO&#xAE; (daratumumab and hyaluronidase-fihj) significantly delayed progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM) and extended overall survival compared to the current standard of care of active monitoring.&nbsp;The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4320032-1&amp;h=2380629267&amp;u=https%3A%2F%2Fash.confex.com%2Fash%2F2024%2Fwebprogram%2FPaper201057.html&amp;a=Abstract+%23773">Abstract #773</a>), as part of the Press Program and were selected for the Best of ASH session.&nbsp;
In the AQUILA study, 194 patients received DARZALEX FASPRO&#xAE; and 196 patients were actively monitored per current standard of care treatment for high-risk SMM. At a median follow-up of 65.2 (range, 0-76.6) months, patients who received DARZALEX FASPRO&#xAE; showed statistically significant improved progression-free survival (PFS; defined as progression to active MM as assessed according to International Myeloma working Group (IMWG) diagnostic criteria for MM [SLiM-CRAB] or death) than the active monitoring group; 63.1 percent versus 40.8 percent of patients remained progression-free at 60 months (hazard ratio [HR], 0.49; 95 percent confidence interval [CI], 0.36-0.67; P&lt;0.001). Among patients who were retrospectively categorized as having high-risk SMM per the current Mayo 2018 criteria (20/2/20), median progression-free survival was not reached in the DARZALEX FASPRO&#xAE; arm and was 22.1 months in the active monitoring arm (HR, 0.36; 95 percent CI, 0.23-0.58). Overall survival was also extended with DARZALEX FASPRO&#xAE;, with 5-year survival rates of 93 percent versus 86.9 percent for active monitoring (HR, 0.52; 95 percent CI, 0.27-0.98).1

Johnson & Johnson Announced Darzalex Faspro Shows Significantly Delayed Progression To Active Multiple Myeloma For Patients With High-risk Smoldering Multiple Myeloma At ASH

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$270.00</td>
<td>$126.0K</td>
<td>711</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$160.00</td>
<td>$162.3K</td>
<td>2.0K</td>
<td>939</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$310.00</td>
<td>$54.2K</td>
<td>71</td>
<td>742</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$830.00</td>
<td>$28.3K</td>
<td>2.0K</td>
<td>520</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$600.00</td>
<td>$96.7K</td>
<td>17</td>
<td>474</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$240.00</td>
<td>$279.3K</td>
<td>1.0K</td>
<td>306</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$89.1K</td>
<td>8.4K</td>
<td>289</td>
</tr>
<tr>
<td>MEDP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$25.8K</td>
<td>224</td>
<td>178</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$25.00</td>
<td>$29.4K</td>
<td>4.1K</td>
<td>145</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$390.00</td>
<td>$28.2K</td>
<td>348</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 13, 2024. This event was a transfer of 618 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $126.0K, with a price of $205.0 per contract. There were 711 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 106 day(s) on March 21, 2025. This event was a transfer of 800 contract(s) at a $160.00 strike. The total cost received by the writing party (or parties) was $162.3K, with a price of $203.0 per contract. There were 2021 open contracts at this strike prior to today, and today 939 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option sweep with bullish sentiment. It expires in 197 day(s) on June 20, 2025. Parties traded 21 contract(s) at a $310.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $2582.0 per contract. There were 71 open contracts at this strike prior to today, and today 742 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be neutral, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 13 contract(s) at a $830.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $2176.0 per contract. There were 2007 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on December 27, 2024. Parties traded 117 contract(s) at a $600.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $96.7K, with a price of $830.0 per contract. There were 17 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on December 6, 2024. Parties traded 266 contract(s) at a $240.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $279.3K, with a price of $1050.0 per contract. There were 1000 open contracts at this strike prior to today, and today 306 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be neutral, expiring in 43 day(s) on January 17, 2025. This event was a transfer of 99 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $89.1K, with a price of $900.0 per contract. There were 8479 open contracts at this strike prior to today, and today 289 contract(s) were bought and sold. 
• Regarding MEDP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), we observe a put option sweep with bullish sentiment. It expires in 15 day(s) on December 20, 2024. Parties traded 30 contract(s) at a $340.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $860.0 per contract. There were 224 open contracts at this strike prior to today, and today 178 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be neutral, expiring in 771 day(s) on January 15, 2027. This event was a transfer of 70 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.4K, with a price of $420.0 per contract. There were 4153 open contracts at this strike prior to today, and today 145 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 47 contract(s) at a $390.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $600.0 per contract. There were 348 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MEDP

10 Health Care Stocks Whale Activity In Today's Session

Ray Dalio-led hedge fund Bridgewater Associates sold its positions in the topmost AI-linked stock along with other big technology companies, while buying shares of other AI-linked companies in the third quarter of the current fiscal as per its 13F filings.
What Happened: Bridgewater pared its stake in Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), among other companies.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Holdings (as of Jun. 30) (in million)</td>
<td>Holdings (as of Sept. 30) (in million)</td>
<td>Change (in million) </td>
<td>Stock Performance (YTD)</td>
</tr>
<tr>
<td>Nvidia</td>
<td>6.556</td>
<td>4.754</td>
<td>-1.8</td>
<td>188%</td>
</tr>
<tr>
<td>Alphabet </td>
<td>4.54</td>
<td>4.37</td>
<td>-0.17</td>
<td>24%</td>
</tr>
<tr>
<td>Microsoft</td>
<td>1.09</td>
<td>0.870</td>
<td>-0.22</td>
<td>16%</td>
</tr>
<tr>
<td>Amazon</td>
<td>2.64</td>
<td>1.41</td>
<td>-1.23</td>
<td>41%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>3.204</td>
<td>1.470</td>
<td>-1.73</td>
<td>-3.2%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/24/12/42282948/ubs-forecasts-sp-500-to-hit-6600-in-2025-citing-support-from-over-easy-global-central-bank-policy">UBS Forecasts S&amp;P 500 To Hit 6,600 In 2025, Citing Support From &#8216;Over-Easy Global Central Bank Policy&#8217;</a>
On the other hand, the hedge fund bought Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) along with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>).
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Holdings (as of Jun. 30) (in million)</td>
<td>Holdings (as of Sept. 30) (in million)</td>
<td>Change (in million)</td>
<td>Stock Performance (YTD)</td>
</tr>
<tr>
<td>Broadcom </td>
<td>0.024</td>
<td>0.955</td>
<td>0.931</td>
<td>53%</td>
</tr>
<tr>
<td>Apple</td>
<td>0.469</td>
<td>1.031</td>
<td>0.562</td>
<td>29%</td>
</tr>
<tr>
<td>Super Micro Computer</td>
<td>0.015</td>
<td>0.161</td>
<td>0.146</td>
<td>47%</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>0.086</td>
<td>0.523</td>
<td>0.437</td>
<td>300%</td>
</tr>
<tr>
<td>Advanced Micro Devices</td>
<td>1.099</td>
<td>1.464</td>
<td>0.365</td>
<td>2.5%</td>
</tr>
</tbody>
</table>
</figure>
Why It Matters: Big tech saw heavy selling at Bridgewater in the third quarter, while it increased its stake in companies like Broadcom by 3,806% to a total value of $164.81 million.
Bridgewater sold 27% or 1.8 million shares of Nvidia reducing its value in its portfolio by $232.59 million. It also sold $100.697 million worth of Google-parent Alphabet&#8217;s stock.
The hedge fund further sold 220.169 million shares of Microsoft and 1.233 million shares of Amazon.
In the same period, Bridgewater increased its stake in Super Micro Computer by 921%, Palantir Tech by 507%, and Advanced Micro Devices by 35%.
The hedge fund founded by Ray Dalio held 1.031 million shares of Apple worth $240.4 million. It also added $92.62 million worth of SPDR S&amp;P 500 ETF increasing the holding by 18% in the exchange-traded fund.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42283257/charles-schwab-goldman-sachs-invesco-add-mara-holdings-morgan-stanley-cuts-stake-here-is-what-changed-with-mara-holdings-in-q3">Charles Schwab, Goldman Sachs Boosts MARA Stake As Stock Rallies 30% In Past 6 Months: Morgan Stanley, Other Major Funds Trim Positions In Q3</a></li>
</ul>
Photo courtesy: World Economic Forum On Flickr

Hedge Funds

AAPL

AVGO

PLTR

SMCI

Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies

Johnson & Johnson Has Submitted Two Supplemental Biologics License Applications To The FDA Seeking Approval Of Tremfya (Guselkumab) For Children 6 Years And Older With Moderate-to-severe Plaque Psoriasis And Children 5 Years Of Age And Older With Active Juvenile Psoriatic Arthritis

Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.
Recently, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) filed a lawsuit against a U.S. government agency over a contentious&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">disagreement about payment methods</a>.
The pharmaceutical giant contends the statute governing the program allows manufacturers to choose between rebate and discount pricing models and claims HRSA's decision undermines this flexibility.
The 340B Drug Pricing Program requires drug manufacturers to sell medications at reduced prices to eligible healthcare providers, known as "covered entities," under specific conditions.
Bristol-Myers has historically used the discount model, offering upfront price reductions. However, the company argues this approach has led to widespread program abuses, including violations of safeguards meant to prevent duplication with Medicaid Drug Rebate Program rebates and diversion of discounted drugs to ineligible recipients.
Bristol-Myers <a href="https://www.statnews.com/wp-content/uploads/2024/11/bristol-vs-hhs-hrsa-340b.pdf" target="_blank" rel="noreferrer noopener">claims</a> these issues are exacerbated by intermediaries such as commercial pharmacies and third-party administrators, who profit from price disparities.
Citing these abuses and insufficient enforcement by HHS, Bristol-Myers announced its intention in October 2024 to transition to a rebate model.
Under this system, covered entities would initially pay the commercial price and later receive a rebate to achieve the 340B price. Bristol-Myers argues this model, explicitly permitted by the 340B statute, would enhance program integrity by reducing opportunities for abuse.
Despite the statutory basis for both models, HRSA determined that Bristol-Myers' proposed shift to a rebate model was inconsistent with the 340B statute and required pre-approval.
Bristol-Myers asserts this decision unlawfully restricts manufacturers' statutory options, violates the Administrative Procedure Act, and represents arbitrary and capricious regulatory overreach.
The company further claims the decision is illogical and contradicts substantive due process principles by imposing irrational constraints.
Eli Lilly And Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has also filed a lawsuit against the HRSA. The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount <a href="https://www.benzinga.com/general/biotech/24/11/42002487/mounjaro-maker-eli-lilly-files-lawsuit-against-us-agency-over-drug-rebate-program" target="_blank" rel="noreferrer noopener">offerings to hospitals</a>.
BMY Price Action: Bristol-Myers Squibb stock is up 0.12% at $59.36&nbsp;at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42246190/whats-going-on-with-hub-cyber-security-stock-today" target="_blank" rel="noreferrer noopener">Hub Cyber Security Powers Up: Major Debt Reduction, Fresh Investment, Board Change &amp; More</a></li>
</ul>
Photo: Courtesy of Bristol Myers Squibb

Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program

Johnson & Johnson Submits Supplemental Biologics License Application To FDA Seeking Approval Of Subcutaneous Induction Regimen Of TREMFYA

Bullish option flow detected in Johnson & Johnson (JNJ) with 12,184 calls trading, 1.0x expected, and implied vol increasing over 1 point to 19.22%...

Johnson & Johnson call volume above normal and directionally bullish

It's a good idea to look at stocks that can give us what we need in the absence of a rally.

The Options Market Is Pointing Us At Four Dividend Stocks Right Now

The following 10 stocks represent Dividend Kings that can continue to raise their dividends for decades to come.

10 Buy And Hold Forever Dividend Stocks

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Johnson & Johnson announced that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercializati...

Johnson & Johnson licensing STAT6 program from Kaken Pharmaceutical

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading... With healthcare companies investing their resources in drug development and the adoption of the latest technologies for improving patients' lives and enhancing the system, the healthcare industry is booming. New-age solutions and technologies allow people to live longer, healthier, more productive, and more independent lives.
Given this backdrop, it could be wise to invest in quality healthcare stocks Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), and Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>), which are revolutionizing patient care.
Revenue in the pharmaceuticals market is expected to reach $1.16 trillion in 2024. Further, the market is anticipated to exhibit growth at a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">CAGR of 4.7%</a>, resulting in a market volume of $1.45 trillion by 2029. In global comparison, the United States is expected to generate the highest revenue of $630.30 billion in 2024 with its advanced healthcare infrastructure and strong R&amp;D capabilities.
The healthcare sector is experiencing strong growth and is currently driven by medical advancements and the latest technologies. In recent times, technology has marked significant strides in healthcare, enabling health providers and hospitals to treat patients better and improve their lives with advanced equipment, systems, and new software.
Also, healthcare companies are investing aggressively in R&amp;D to develop the latest drugs and solutions to aid the current healthcare system. Over 44 new medicines have been <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approved by the U.S. FDA in 2024</a>, targeting conditions and diseases like non-small cell lung cancer, acute leukemia, metastatic breast cancer, and hypoparathyroidism.
Further, technologies like Artificial Intelligence (AI), telemedicine, 3D printing, virtual reality, robotics, and electronic health records are contributing to efficient operations and procedures, revolutionizing aspects like drug discovery, patient care, patient monitoring, and labor-related issues. Notably, the <a href="https://www.advamed.org/medical-device-industry-facts/#:~:text=Medical%20technology%20saves%20lives%2C%20improves,paying%20jobs%20across%20the%20country.">U.S. is the largest medical device market</a> globally, comprising over 40% of the global medtech market.
Given these factors, let's delve deeper into the fundamentals of the top <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> stocks, starting with the third choice.
Stock #3: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells various healthcare sector products internationally. The company operates in the Innovative Medicine and MedTech segments. It provides products for various therapeutic areas, like immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis.
On November 21, JNJ announced that Health Canada has issued a Notice of Compliance for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for treating adult patients with multiple myeloma who have received therapy and who are refractory to lenalidomide. With the approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen-targeted approved therapy.
The approval marks a major milestone for patients with multiple myeloma. Clinical trials have shown that CARVYKTI&#xAE; can significantly lower the risk of disease progression or death compared to the current standard of care.
On November 12, JNJ received the U.S. FDA approval for its OTTAVA&#x2122; robotic surgical system investigational device exemption (IDE), which allows the clinical trial to begin at U.S. sites. JNJ is building on its global portfolio of surgical technologies to advance OTTAVA and help hospitals provide robotic surgery benefits to more patients.
The system will benefit patients and surgeons and address the unmet needs that persist in robotic surgery.
During the third quarter that ended September 29, 2024, JNJ's sales to customers increased 5.2% year-over-year to $22.47 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> grew 5.2% from the year-ago value to $15.51 billion. The company's adjusted net earnings from continuing operations came in at $5.88 billion and $2.42 per share for the quarter, respectively.
Street expects JNJ's revenue for the fiscal year (ending December 2024) to increase 4.3% year-over-year to $88.79 billion, and its EPS for the same year is estimated to grow marginally year-over-year to $9.96. Further, the company has surpassed the consensus EPS estimates in each of the trailing four quarters.
JNJ's stock has soared 1.1% over the past six months and 2.1% over the past year to close the last trading session at $153.
JNJ's solid prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Quality, Stability, Sentiment, and Value. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, JNJ is ranked #13 in the list of 155 stocks.
<a href="https://stocknews.com/stock/JNJ/">Click here</a> to access additional JNJ ratings for Growth and Momentum.
Stock #2: Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK operates as a healthcare company globally. The company operates in two segments: Pharmaceutical and Animal Health. It offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands.
On December 3, MRK was granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) by the U.S. FDA for treating patients with advanced or metastatic nonsquamous non-small cell lung cancer with epidermal growth factor receptor mutations.
Sac-TMT is an investigational trophoblast cell-surface antigen 2-directed antibody-drug conjugate being developed in collaboration with Kelun-Biotech.
On November 22, MRK announced that the National Medical Products Administration (NMPA) in China approved its WELIREG&#xAE; (belzutifan), for the treatment of adult patients with von Hippel-Lindau (VHL) disease.
During the third quarter that ended September 30, 2024, MRK reported sales of $16.66 billion, up 4.4% year-over-year, and its income before taxes was $4.09 billion for the period. The company's non-GAAP net income and non-GAAP EPS came in at $3.98 billion and 1.57 for the quarter, respectively.
The consensus EPS estimate of $1.81 for the fourth quarter (ending December 2024) represents a 5943.9% improvement year-over-year. The consensus revenue estimate of $15.47 billion for the same quarter reflects a 5.8% increase from last year. Also, MRK topped the consensus revenue and EPS estimates in all four trailing quarters.
MRK's stock has plunged 3% over the past month to close the last trading session at $99.75.
MRK's bright outlook is reflected in its POWR Ratings. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
MRK has an A grade for Quality and a B for Stability and Value. MRK is ranked #6 out of 155 stocks in the Medical – Pharmaceuticals industry.
<a href="https://stocknews.com/stock/MRK/">Click here</a> to access MRK's other ratings for Growth, Momentum, and Sentiment.
Stock #1: Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>)
BMY discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company provides products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
On November 15, BMY received Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval for Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient.
On the same date, BMY received CHMP of the EMA recommended approval for repotrectinib, which is a next-generation tyrosine kinase inhibitor, for treating adult patients with ROS1-positive advanced non-small cell lung cancer and for treating adult and pediatric patients above 12 years of age with advanced solid tumors expressing a NTRK gene fusion.
BMY's total revenues increased 8.4% year-over-year to $11.89 billion for the third quarter that ended September 30, 2024. Its non-GAAP gross profit grew 6.6% from the year-ago value to $9.04 billion. Furthermore, non-GAAP net earnings attributable to BMS and EPS totaled $3.65 billion and $1.80 for the quarter, respectively.
Analysts expect BMY's revenue for the fourth quarter (ending December 2024) to increase marginally year-over-year to $11.54 billion, and its EPS is expected to be $1.47 for the ongoing quarter. Also, the company has topped the consensus revenue estimates in all of the trailing four quarters.
Shares of BMY have gained 31.7% over the past six months and 10.9% over the past year to close the last trading session at $56.65.
BMY's POWR Ratings reflect its robust outlook. BMY has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
The stock has an A grade for Growth. It also has a B grade for Quality, Stability, Sentiment, and Value. BMY has topped among the 155 stocks in the same industry.
<a href="https://stocknews.com/stock/BMY/">Click here</a> to access all BMY ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares were trading at $146.15 per share on Thursday afternoon, down $0.49 (-0.33%). Year-to-date, JNJ has declined -3.80%, versus a 28.50% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/jnj-mrk-bmy-3-healthcare-innovators-revolutionizing-patient-care/>3 Healthcare Innovators Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Innovators Revolutionizing Patient Care

FDA proposes testing talc products for asbestos: report

How To Build A Strategically Balanced $50,000 Dividend Portfolio To Be Well-Positioned For 2025

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a "positive readthrough" fr...

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal

FDA proposes asbestos-testing standards for talc products (update)

ARCC

AZNCF

BBSEY

COTY

KAPA

KVUE

KYMR

LRLCF

MAIN

QCOM

SCHD

SCHO

TCPC

VICI

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) Forecast

Johnson & Johnson (NYSE:JNJ) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga